These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21729856)

  • 1. Bosentan.
    Bell SG
    Neonatal Netw; 2011; 30(4):249-51. PubMed ID: 21729856
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary Hypertension in a Premature Infant With Bronchopulmonary Dysplasia.
    Ruffini L
    J Pediatr Health Care; 2015; 29(5):463-9. PubMed ID: 25843805
    [No Abstract]   [Full Text] [Related]  

  • 3. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension].
    Xu ZM; Zhu LM; Cai XM; Ji G; Liu JF; Su ZK
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2106-9. PubMed ID: 20058613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia.
    Rugolotto S; Errico G; Beghini R; Ilic S; Richelli C; Padovani EM
    Minerva Pediatr; 2006 Oct; 58(5):491-4. PubMed ID: 17008861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
    Mohamed WA; Ismail M
    J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
    Blok IM; van Riel ACMJ; van Dijk APJ; Mulder BJM; Bouma BJ
    Int J Cardiol; 2017 Jan; 227():51-52. PubMed ID: 27846462
    [No Abstract]   [Full Text] [Related]  

  • 10. Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.
    Ghanbari H; Feldman D; David S; Saba S
    Circ Cardiovasc Imaging; 2009 Nov; 2(6):e46-8. PubMed ID: 19920035
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of bosentan in patients with a failing Fontan circulation.
    Ovaert C; Thijs D; Dewolf D; Ottenkamp J; Dessy H; Moons P; Gewillig M; Mertens L
    Cardiol Young; 2009 Aug; 19(4):331-9. PubMed ID: 19519964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PAH in congenital heart defects--therapeutic experiences with children and adults].
    Schulze-Neick I
    Kinderkrankenschwester; 2005 Jun; 24(6):259-60. PubMed ID: 16025782
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bosentan in pulmonary hypertension].
    Heinzl S
    Med Monatsschr Pharm; 2002 Mar; 25(3):74-6. PubMed ID: 11925765
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bosentan].
    Taéron C
    Rev Infirm; 2005 Feb; (108):33-4. PubMed ID: 15816717
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
    Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O; Griffiths L; Clarke B; Mahadevan VS
    Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bosentan: a new pillar in the treatment of pulmonary hypertension?].
    Matthes J; Groner F
    Dtsch Med Wochenschr; 2006 May; 131(18):1031-4. PubMed ID: 16673229
    [No Abstract]   [Full Text] [Related]  

  • 19. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.
    Beghetti M; Hoeper MM; Kiely DG; Carlsen J; Schwierin B; Segal ES; Humbert M
    Pediatr Res; 2008 Aug; 64(2):200-4. PubMed ID: 18414142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.